Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Another Strong Quarter, WuXi Aims To Become Backbone Of China’s Life Science Industry: China Earnings Roundup (Part 1)

This article was originally published in PharmAsia News

Executive Summary

Despite a macroeconomic slowdown, China’s leading CRO reported another strong quarter due to increasing demand for R&D services from both international and domestic companies.

You may also be interested in...



China's Leading CROs Go On Shopping Spree To Become One-Stop Vendors

China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas

China's Leading CRO WuXi Looks To Utilize Manufacturing Capacity With Telaprevir

SHANGHAI - Leading Chinese contract research organization WuXi PharmaTech Co., Ltd. recorded a strong quarter with revenue up 16% over the same period last year to $93.6 million, and the company is readying itself for big increases in its manufacturing business thanks to large-scale contracts generated from discovery deals

Are China's Rising Labor Costs Good For Big Pharma?

HONG KONG - Rising labor costs are putting stress on manufacturing operations in China, but may prove to be a boon in the long term for companies focused on the world's fastest-growing domestic market

Topics

Related Companies

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel